ImageneBio, Inc.

IMA Healthcare Biotechnology

ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 12.5% and free cash flow grew 23.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.04 0.01 +0.25%
Market cap
$45.7M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
3/9
Altman Z
−1.12
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
21.47 18.39 12.49 13.24
Net Debt/EBITDA
11.73 9.84 16.96 5.42
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.56) (1.32) (1.48) (2.52)
Book value per Share
8.79 11.00 27.33 16.40
Free Cash Flow
(9.07) (14.80) (7.22) (21.49)
Other line items

Show all line items

Columns are period end dates